- German dialysis provider Fresenius Medical Care (NYSE:FMS) has agreed to acquire U.S. home dialysis device maker NxStage (NASDAQ:NXTM) for around $2B in cash.
- FMC expects the deal to result in cost synergies of around $80M-$100M per year before tax and to be accretive to net income and earnings within three years of closing.
- NXTM +25.5% premarket
FMC to buy NxStage for $2B
Recommended For You
About FMS Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| FMS | - | - |
| Fresenius Medical Care AG | ||